Clinical Trial Update: Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial investigating ibrutinib in high risk smoldering multiple myeloma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: High Risk Smoldering Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2020-12-16